No Insurance? No Colonoscopy
Main Category: Colorectal CancerAlso Included In: Health Insurance / Medical Insurance; Public Health
Article Date: 08 May 2009 - 1:00 PDT
| Patient / Public: | ![]() |
4.33 (3 votes) |
| Healthcare Prof: | ![]() |
John M Inadomi highlights the disparity in colorectal cancer screening (CRCS) among different socioeconomic and ethnic groups in US society in a recent review published by F1000 Medicine Reports.
Colorectal cancer is the second leading cause of cancer-related death in the developed world. In this report, John Inadomi, chief of Clinical Gastroenterology at the San Francisco General Hospital and a frequent contributor to F1000 Medicine, writes that the uptake of certain types of screening has been linked to inadequate medical insurance amongst the poorer socio-economic and ethnic groups.
Of the several screening modalities currently available, colonoscopy, sigmoidoscopy and fecal occult blood testing (FOBT) have been shown to reduce colorectal cancer incidence or mortality. Inadomi draws attention to the high prevalence of 'flat' colonic lesions since some screening methods are less likely to detect flat lesions, patients who opt for these modalities (e.g. for financial reasons) could be at risk of lesions being missed.
One study cited in Inadomi's report found that "African-American women were half as likely as white women to report having undergone screening by colonoscopy." Added to this, awareness of the different tests for CRCS was significantly lower among African-Americans than whites. Correspondingly, there was a similar significant difference in lack of medical insurance coverage between these groups.
New technologies used in rural primary care practice to educate people to different types of CRCS have proven to raise the number of patient intention to get screened, helping to overcome socio-economic barriers.
While recognising that language, culture and economic inequality remain significant barriers, Inadomi is optimistic about "the use of new technology and techniques for disseminating information among patients and their providers", and concludes that the efficacy of CRCS may be better improved by "specific educational interventions" than by any given advance in current screening technologies.
Dr John M Inadomi, Faculty Member for F1000 Medicine, is Associate Professor of Clinical Medicine and chief of Clinical Gastroenterology at the San Francisco General Hospital
Full text of the F1000 Medicine Reports article.
Source:
Kathleen Wets
Faculty of 1000: Biology and Medicine
Visit our colorectal cancer section for the latest news on this subject.
MLA
16 Feb. 2012. <http://www.medicalnewstoday.com/releases/149301.php>
APA
http://www.medicalnewstoday.com/releases/149301.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.





